- Open Access
Prostate-specific antigen and hormone receptor expression in male and female breast carcinoma
© Kraus et al; licensee BioMed Central Ltd. 2010
- Received: 9 June 2010
- Accepted: 23 September 2010
- Published: 23 September 2010
Prostate carcinoma is among the most common solid tumors to secondarily involve the male breast. Prostate specific antigen (PSA) and prostate-specific acid phosphatase (PSAP) are expressed in benign and malignant prostatic tissue, and immunohistochemical staining for these markers is often used to confirm the prostatic origin of metastatic carcinoma. PSA expression has been reported in male and female breast carcinoma and in gynecomastia, raising concerns about the utility of PSA for differentiating prostate carcinoma metastasis to the male breast from primary breast carcinoma. This study examined the frequency of PSA, PSAP, and hormone receptor expression in male breast carcinoma (MBC), female breast carcinoma (FBC), and gynecomastia.
Immunohistochemical staining for PSA, PSAP, AR, ER, and PR was performed on tissue microarrays representing six cases of gynecomastia, thirty MBC, and fifty-six FBC.
PSA was positive in two of fifty-six FBC (3.7%), focally positive in one of thirty MBC (3.3%), and negative in the five examined cases of gynecomastia. PSAP expression was absent in MBC, FBC, and gynecomastia. Hormone receptor expression was similar in males and females (AR 74.1% in MBC vs. 67.9% in FBC, p = 0.62; ER 85.2% vs. 68.5%, p = 0.18; and PR 51.9% vs. 48.2%, p = 0.82).
PSA and PSAP are useful markers to distinguish primary breast carcinoma from prostate carcinoma metastatic to the male breast. Although PSA expression appeared to correlate with hormone receptor expression, the incidence of PSA expression in our population was too low to draw significant conclusions about an association between PSA expression and hormone receptor status in breast lesions.
- Androgen Receptor
- Progesterone Receptor
- Prostate Specific Antigen
- Male Breast
Extramammary malignancies metastatic to the breast reportedly represent 0.46 - 5% of all malignant breast fine needle aspiration biopsies in females and males. Incidence rates of metastasis to the breast as high as 6.6% have been reported when hematologic malignancies are included. Prostatic carcinoma is among the most commonly reported solid tumors to secondarily involve the male breast. In one study, 26% of patients with a known history of prostate carcinoma were found to have metastases to the breast at autopsy.
Metastatic neoplasms to the breast generally occur in the setting of disseminated metastatic disease, however patients may present with a breast mass as the first manifestation of metastatic cancer. Metastatic malignancies involving the breast are associated with a poor prognosis, with the majority of patients dying within one year of diagnosis[7–9]. Treatment generally involves systemic chemotherapy, and correct diagnosis is essential to provide accurate prognostic information and prevent unnecessary surgery in these patients.
Reports of prostate specific antigen (PSA) expression in male and female breast carcinomas[3, 10–15] have raised questions about the value of PSA staining in differentiating metastatic prostatic carcinoma from primary breast carcinoma. PSA expression has been reported to correlate with expression of androgen receptor (AR), estrogen receptor (ER) and progesterone receptor (PR) in some studies[10, 13], however other studies have found no correlation.
The aim of this study was to assess the frequency of PSA and prostate specific acid phosphatase (PSAP) expression in male breast carcinoma (MBC), female breast carcinoma (FBC) and gynecomastia and to correlate these findings with hormone receptor expression.
A search of electronic medical records from the Emory University Healthcare system was conducted to identify cases of MBC, FBC, and gynecomastia. With Institutional Review Board approval from Emory University (IRB00012568, 517-2002), tissue microarrays (TMAs) representing six cases of gynecomastia (four 0.1-cm cores per case), thirty MBC (four cores per case), and fifty-six FBC (two cores per case) were constructed from paraffin-embedded tissue blocks of surgical specimens.
Antibodies and Interpretation Criteria
Any cytoplasmic staining
Any cytoplasmic staining
Nuclear staining ≥ 10%
Nuclear staining ≥ 10%
Nuclear staining ≥ 10%
The sections were deparaffinized and rehydrated in deionized water. Antigen retrieval was in heated citrate buffer (pH 6.0), using an electric pressure cooker for 3 minutes at 12-15 pounds per square inch (approximately 120°C); slides were cooled for 10 minutes prior to immunostaining.
The slides were loaded on the Dako AutoStainer Plus (Dako) and exposed to 3% hydrogen peroxide for five minutes, incubated at room temperature with primary antibody for 30 minutes, followed by labeled polymer (Envision+dual link) for thirty minutes, 3,3'-diaminobenzidine as a chromogen for five minutes, and hematoxylin counterstain for five minutes.
PSA and PSAP were considered positive if any cytoplasmic staining was observed. Positive reactions for AR, ER, and PR were defined by nuclear staining observed in at least 10% of tumor cells.
P-values for hormone receptor status of FBC and MBC were determined by Fisher's exact test.
PSA, PSAP, and Hormone Receptor Expression in MBC, FBC, and Gynecomastia.
P-value (MBC vs FBC)
Grading and Staging Data for PSA-Positive Cases
Lymph Node Status
PSA+ (diffuse), PSAP-,
AR-, ER-, PR-
PSA+ (focal), PSAP- AR+, ER+, PR+
PSA+ (focal), PSAP-, AR+, ER+, PR+
Prostate carcinoma has been reported to be the most common metastatic malignancy to the male breast. Lung cancer and melanoma are also among the commonly reported neoplasms that secondarily involve the male breast. While the treatment for primary breast carcinoma involves surgical resection, treatment of metastatic carcinoma to the breast generally involves systemic therapy. Thus, accurate diagnosis is essential to prevent unnecessary surgery and provide optimal treatment and prognostic information to these patients.
Radiographic clues may aid in the differentiation of primary breast carcinoma from metastatic disease, as primary lesions tend to be spiculated and metastases are often more discrete and rounded[4, 5, 7, 8]. Calcifications are more likely to occur in primary breast carcinomas[5, 7, 8]. Histologically, the presence of carcinoma in situ and elastosis are more commonly encountered in primary breast carcinoma than in metastatic tumors. Nonetheless, metastatic malignancies may closely mimic primary breast carcinoma in imaging studies and on histologic examination, and definitive diagnosis often depends on immunohistochemical studies.
PSA and PSAP are commonly used to suggest prostatic origin of malignant cells. PSA is a 33 kD glycoprotein with serine protease activity. The detection of PSA in tissues by immunohistochemical staining is widely used to confirm the prostatic origin of carcinoma. Though initially thought to be specific to the prostate gland, PSA has been detected in other tissues, including the parotid, pancreas, and kidney, carcinomas of the ovary, lung, and breast, neuroendocrine cells, and benign breast lesions.
PSAP is a tyrosine phosphatase involved in growth regulation, and is regarded as a less sensitive, more specific marker of prostatic origin of cells. According to Erbas et al., PSAP was detected in breast cyst fluid samples by ELISA; however, immunohistochemically detectable PSAP expression was not identified in breast carcinomas or gynecomastia in previous studies[2, 3, 12, 19].
Immunohistochemical detection of PSA and PSAP has been useful in the diagnosis of prostate carcinoma metastasis to the breast. Cheng et al. reported one such case, and reviewed 33 additional cases from the literature. PSA expression was identified in 12 of 12 cases (100%) and PSAP expression in 13 of 14 cases (92.8%) where immunohistochemistry was performed.
Our series represents the largest group of MBCs to be tested for immunohistochemically detectable PSA expression, performed in conjunction with a significant number of FBCs.
In our population, PSA expression was not detected in gynecomastia, and was uncommon in both male and female breast cancers. PSAP expression was not detected in benign or malignant breast tissue, similar to previous reports [2, 3, 12, 19].
Previous Reports of Immunohistochemically Detectable PSA Expression in Benign and Malignant Breast Lesions
Number of Cases
Carder et al. 2005 
Dako, ELY, Cambridgeshire, UK
Focal intense staining
All cases PSAP negative (Dako)
Cheng et al. 2006 
Dako, Glostrup, Denmark
All cases PSAP negative
Ilvan et al. 2004 
Dako USA, monoclonal, prediluted
All PSA positive cases ER+ PR+
Miller et al. 2001 
75 (74 FBC, 1 MBC)
Dako M0750 1:320
5/7 showed weak, focal positivity; MBC negative
Kidwai et al. 2003 
Dako polyclonal 1:1800
5 focally positive
All PSAP negative
Narita et al. 2006 
Dako polyclonal, ready to use
Positive correlation with AR expression
Hall et al. 1998 
Dako, Carpinteria, CA
Alanen et al. 1999 
Dakopatts, Glostrup, Denmark, polyclonal 1:1000
Gatalica et al. 1999 
18 gynecomastia, 8 MBC
Rabbit polyclonal, Ventana Medical Systems, Tucson AZ
5/18 cases of gynecomastia (27.8%)
Focal strong polyclonal PSA; 4/5 cases tested with monoclonal PSA and were negative
All cases PSAP (Ventana PASE/4LT) negative
Quraishi et al. 2007 
30 (8 DCIS, 19 infiltrating ductal carcinoma, 3 metastatic breast carcinoma)
Gupta 1999 
Cell blocks positive; trace PSA positivity in resection specimens
Tanaka et al. 2002 
Dako A/S Glostrup, Denmark, polyclonal 1:100
6 cases strongly positive
Dako polyclonal 1:10,000
All cases PSAP negative
The frequency of PSA expression in our series of breast carcinomas was lower than in a report by Kidwai et al. (2003), where PSA positivity was observed in six of 26 cases of MBC (23%). Although staining for PSA was focal in five of the positive cases, one case was diffusely positive. The polyclonal PSA antibody used in our study was similar to that used by Kidwai et al. Other studies, most of which focused predominantly on FBC, have reported results similar to those described by Kidwai et al.[3, 10, 13, 15, 22]
Our results are similar to those reported by Carder et al. and Gatalica et al., who noted PSA positivity in one of eleven MBCs (9.1%) and zero of eight MBCs (0%), respectively. In the latter study, five of eighteen cases of gynecomastia (27.8%) showed staining for polyclonal PSA. When a monoclonal PSA antibody was used, however, only one case remained positive (5.6%).
Based on previous reports, PSA expression appears to be less common in MBC than in FBC. When taken together, the overall incidence of PSA expression in breast cancer cases reported in the literature is 28.5% (215 of 754 total cases; range 0%[3, 19, 20] to 100%). When only MBC is considered, the incidence is 14.5% (9 of 62 cases; range 0%[3, 19] to 100%). When our cases are included, the overall incidence is 26% (218 of 836 cases) and the incidence in MBC is 11% (10 of 92 cases). In contrast to previous studies, the percentage of PSA-positive FBC cases was similar to the percentage of PSA-positive MBC cases in our study.
The physiologic significance of PSA expression in extraprostatic tissues is not known. Though PSA has been shown to hydrolyze or otherwise modify substrates such as fibrinogen and laminin, its function (if any) in breast tissue and its prognostic significance in breast carcinoma remain unclear. Previous reports have suggested a relationship between PSA expression and carcinomas of low histologic grade[14, 15]. In the current study, PSA expression did not appear to be associated with grade. PSA-positive tumors were either well-differentiated or poorly differentiated, and PSA-negative tumors were fairly evenly distributed between histologic grades I (23%), II (39%), and III (38%) (data not shown).
PSA positivity in breast cancer cells has also been reported to correlate with hormone receptor positive status and possibly with improved prognosis, although other studies have found no such association. PSA expression has been induced by androgens, progesterone, and glucocorticoids in steroid receptor-positive breast cancer cell lines, suggesting that PSA expression in breast tumors is indeed under hormonal control. In a study of 61 PSA-positive FBC, Narita et al. reported that 57 cases (93.4%) were AR-positive, 28 (46%) were ER-positive, and 22 (36%) were PR-positive. In our study, two of three PSA-positive carcinomas were positive for AR, ER, and PR, and the hormone receptor-negative case demonstrated focal weak AR expression that did not meet our 10% threshold for AR positivity. Our results suggest a correlation between PSA expression and expression of hormone receptors, though the incidence of PSA expression in our population was too low to draw any significant conclusions about this association.
Our data suggest that immunohistochemically detectable expression of PSA and PSAP in male and female breast carcinomas is infrequent. Thus, PSA and PSAP remain viable and useful markers for differentiating primary breast carcinoma from metastatic prostatic carcinoma involving the male breast. As with any immunohistochemical stain, however, these markers should be used in conjunction with clinical history, radiology, and histologic findings.
- Green LK, Klima M: The use of immunohistochemistry in metastatic prostatic adenocarcinoma to the breast. Hum Pathol. 1991, 22 (3): 242-6. 10.1016/0046-8177(91)90157-K.View ArticlePubMedGoogle Scholar
- Carder PJ, et al: Expression of prostate specific antigen in male breast cancer. J Clin Pathol. 2005, 58 (1): 69-71. 10.1136/jcp.2004.018291.PubMed CentralView ArticlePubMedGoogle Scholar
- Cheng CW, et al: Breast metastasis from prostate cancer and interpretation of immunoreactivity to prostate-specific antigen. Int J Urol. 2006, 13 (4): 463-5. 10.1111/j.1442-2042.2006.01327.x.View ArticlePubMedGoogle Scholar
- Wood B, et al: Diagnosis of extramammary malignancy metastatic to the breast by fine needle biopsy. Pathology. 2008, 40 (4): 345-51. 10.1080/00313020801911520.View ArticlePubMedGoogle Scholar
- Muttarak M, Nimmonrat A, Chaiwun B: Metastatic carcinoma to the male and female breast. Australas Radiol. 1998, 42 (1): 16-9. 10.1111/j.1440-1673.1998.tb00556.x.View ArticlePubMedGoogle Scholar
- Salyer WR, Salyer DC: Metastases of prostatic carcinoma to the breast. J Urol. 1973, 109 (4): 671-5.PubMedGoogle Scholar
- Lee AH: The histological diagnosis of metastases to the breast from extramammary malignancies. J Clin Pathol. 2007, 60 (12): 1333-41. 10.1136/jcp.2006.046078.PubMed CentralView ArticlePubMedGoogle Scholar
- Vizcaino I, et al: Metastasis to the breast from extramammary malignancies: a report of four cases and a review of literature. Eur Radiol. 2001, 11 (9): 1659-65. 10.1007/s003300000807.View ArticlePubMedGoogle Scholar
- Yan Z, et al: Prostatic adenocarcinoma metastatic to the breasts: report of a case with diagnosis by fine needle aspiration biopsy. Urology. 2000, 55 (4): 590-10.1016/S0090-4295(99)00560-9.View ArticlePubMedGoogle Scholar
- Ilvan S, et al: Immunohistochemical analysis of prostate-specific antigen in female breast cancer. J BUON. 2004, 9 (2): 183-6.PubMedGoogle Scholar
- Miller MK, Unger PD, Bleiweiss IJ: Immunohistochemical analysis of prostate specific antigen in breast cancer. Breast Cancer Res Treat. 2001, 68 (2): 111-6. 10.1023/A:1011959127928.View ArticlePubMedGoogle Scholar
- Kidwai N, et al: Expression of androgen receptor and prostate-specific antigen in male breast carcinoma. Breast Cancer Res. 2004, 6 (1): R18-23. 10.1186/bcr733.PubMed CentralView ArticlePubMedGoogle Scholar
- Narita D, et al: Immunohistochemical expression of androgen receptor and prostate-specific antigen in breast cancer. Folia Histochem Cytobiol. 2006, 44 (3): 165-72.PubMedGoogle Scholar
- Hall RE, et al: Prostate-specific antigen and gross cystic disease fluid protein-15 are co-expressed in androgen receptor-positive breast tumours. Br J Cancer. 1998, 78 (3): 360-5.PubMed CentralView ArticlePubMedGoogle Scholar
- Alanen KA, et al: Immunohistochemical labelling for prostate-specific antigen in breast carcinomas. Breast Cancer Res Treat. 1999, 56 (2): 169-76. 10.1023/A:1006210627219.View ArticlePubMedGoogle Scholar
- Siddiqui MT, et al: Breast masses in males: multi-institutional experience on fine-needle aspiration. Diagn Cytopathol. 2002, 26 (2): 87-91. 10.1002/dc.10066.View ArticlePubMedGoogle Scholar
- Bostwick DG: Prostate-specific antigen Current role in diagnostic pathology of prostate cancer. Am J Clin Pathol. 1994, 102 (4 Suppl 1): S31-7.PubMedGoogle Scholar
- Erbas H, Erten O, Irfanoglu ME: Prostatic acid phosphatase in breast cyst fluid. Malays J Pathol. 2007, 29 (2): 95-9.PubMedGoogle Scholar
- Gatalica Z, Norris BA, Kovatich AJ: Immunohistochemical localization of prostate-specific antigen in ductal epithelium of male breast. Potential diagnostic pitfall in patients with gynecomastia. Appl Immunohistochem Mol Morphol. 2000, 8 (2): 158-61. 10.1097/00022744-200006000-00011.PubMedGoogle Scholar
- Quraishi I, et al: Clinical validation of breast cancer biomarkers using tissue microarray technology. Appl Immunohistochem Mol Morphol. 2007, 15 (1): 45-9. 10.1097/01.pai.0000213129.86288.34.View ArticlePubMedGoogle Scholar
- Gupta RK: Immunoreactivity of prostate-specific antigen in male breast carcinomas: two examples of a diagnostic pitfall in discriminating a primary breast cancer from metastatic prostate carcinoma. Diagn Cytopathol. 1999, 21 (3): 167-9. 10.1002/(SICI)1097-0339(199909)21:3<167::AID-DC4>3.0.CO;2-W.View ArticlePubMedGoogle Scholar
- Tanaka A, et al: Fibroblast growth factor 8 expression in breast carcinoma: associations with androgen receptor and prostate-specific antigen expressions. Virchows Arch. 2002, 441 (4): 380-4. 10.1007/s00428-002-0687-9.View ArticlePubMedGoogle Scholar
- Black MH, Diamandis EP: The diagnostic and prognostic utility of prostate-specific antigen for diseases of the breast. Breast Cancer Res Treat. 2000, 59 (1): 1-14. 10.1023/A:1006380306781.View ArticlePubMedGoogle Scholar
- Zarghami N, Grass L, Diamandis EP: Steroid hormone regulation of prostate-specific antigen gene expression in breast cancer. Br J Cancer. 1997, 75 (4): 579-88.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.